Orladeyo Now Available to Eligible HAE Patients in Germany

Orladeyo Now Available to Eligible HAE Patients in Germany

295979

Orladeyo Now Available to Eligible HAE Patients in Germany

Orladeyo (berotralstat), an oral therapy to prevent hereditary angioedema (HAE) attacks, is now available to patients, 12 and older, in Germany. “We have an experienced team in place in Germany that is excited and honored to bring the first oral, once daily therapy to HAE patients in Europe,” Charlie Gayer, chief commercial officer of BioCryst Pharmaceuticals, which developed the therapy, said in a press release. “Patients and physicians across Europe have told us about the…

You must be logged in to read/download the full post.